Cost effectiveness of pharmacogenomics: a critical and systematic review. - Wikidata - awgldk - TriplyDB

Cost effectiveness of pharmacogenomics: a critical and systematic review.

Cost effectiveness of pharmacogenomics: a critical and systematic review.

http://www.wikidata.org/entity/Q37799352

about

Economic evaluations of personalized medicine: existing challenges and current developments Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Pharmacogenomics and individualized medicine: translating science into practice.Emerging roles for pharmacists in clinical implementation of pharmacogenomics Cost of illness in colorectal cancer: an international review.Concepts of 'personalization' in personalized medicine: implications for economic evaluation.Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.Pharmacogenomics in early-phase clinical development Stratified medicine and reimbursement issues.GUCY2C molecular staging personalizes colorectal cancer patient management A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.The economic value of personalized medicine tests: what we know and what we need to know.Are patients willing to incur out-of-pocket costs for pharmacogenomic testing?Pharmacogenomics and adverse drug reactions in children.Pharmacometabonomics and personalized medicine.The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence.Complexities of CYP2D6 gene analysis and interpretation.Is individualized medicine more cost-effective? A systematic review.Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?The economic considerations and implications of the stratification of future oncology therapeutics.Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist.Clinical applications of CYP genotyping in psychiatry.Economics of stratified medicine in rheumatoid arthritis.Systematic review of the quality of economic evaluations in the otolaryngology literature.Systematic review of cost-effectiveness analyses of treatments for psoriasis.Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Metabolomics applications in precision medicine: An oncological perspective.A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality.A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine.Exploring rates of abnormal pharmacogenetic findings in a pain practice.Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations.Benefit of pre-emptive pharmacogenetic information on clinical outcome.A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.Risk, reward, and the double-edged sword: perspectives on pharmacogenetic research and clinical testing among Alaska Native people.

P2860

Q26797183-27FA1648-562F-482D-8892-0AEC8EC7C150 Q30612258-EE6CD69C-CF29-4B46-90CC-FAD5DB525262 Q34026161-0F7E4FB3-7307-4D77-92F3-DBB596C2A812 Q34297575-9B9B6A84-E75F-41A3-8DD0-A56E429D78F1 Q34302434-FCE50C8E-4799-4D02-AD19-843681D13B71 Q34699421-6E6989D6-2E55-4BB4-80C0-5E1AC7718A8B Q35575935-3B8CE3A0-1112-43E1-9F44-93123BF1E0DB Q35617340-A1CE4F78-BDF4-4C79-83CF-0C983D102EF2 Q35890606-1788E092-928D-4493-BEB9-4353AAE51A62 Q36001208-8F0F7EE2-60C1-43E6-951C-A18E7E547628 Q36317504-BB07D225-93A4-4171-8449-CB31BEA034D7 Q36336227-888D2B19-E461-49AF-B198-4B9734F02296 Q36541715-96F53319-E03A-44C8-9008-B93FE0C9DC96 Q36709301-B2099EDA-F2CA-44DF-BE9B-DB04AAC84529 Q36883280-6B601E1C-E0E8-4DD2-BE17-826D938C8219 Q37133974-7E1D8A0C-99A8-40E8-A7B8-B917CA841CAE Q37629385-C8A74E4A-E711-4743-8293-B151E60D2659 Q37643815-A581807B-6918-41EB-B959-87388E980A6D Q37719025-1551BB37-D1A8-4AF1-A84B-8173FC779D7F Q38124254-34FA9348-FAD0-4AFD-B73F-8E24B74FD195 Q38153808-7390FAD2-11EC-43E6-8493-63FE84D57BDE Q38154914-F328B52E-9FA3-4CA1-A2D2-02E54A9DB5B3 Q38191496-05DC5035-C07C-4758-BEA6-1240E5A2CBED Q38210051-B0298300-71E4-41CA-A156-E540E656546A Q38211622-12DEE936-1394-4377-9A8E-F71F0DD05D26 Q38241709-A2615D64-0485-4F4D-ADA0-4A7DF84B5935 Q38247063-F62B6A02-1F84-4DBE-99B0-B7D8810DCCA8 Q38264743-2FDDAFE9-FF56-495D-B72D-25DDCD55077C Q38266844-0805C70D-825D-4380-99E1-219D3E65F55A Q38283299-DBB9FA58-F5EC-4C89-8E9C-4626A573890D Q38671676-84395DFC-EE96-49E7-9F35-DD87E888074A Q38689857-CC07DAED-D46D-487C-ACE6-85DD84E8CF6B Q38777644-A137A032-4F5F-4E03-82AB-0673426558FB Q38904691-9741FD80-8079-4BCF-9F58-FD9FA6B09865 Q40549451-31C3EC7D-AA96-44E9-AC31-BF4B8216A109 Q45770718-D08AC10A-7E9B-48B2-AF07-04B69E1419DA Q48130104-C7AEE516-6206-4D5A-B137-17E64BFA9716 Q49612005-ADC8E63C-3C46-46FB-9C6F-8EF5206A7855 Q50432917-E1C979C8-E5A0-44D4-AE49-6F2B0E9C3091 Q52303346-9BE7AE26-24B4-4DA5-8CAB-D56A79909C54

P2860

Cost effectiveness of pharmacogenomics: a critical and systematic review.

http://www.wikidata.org/entity/Q37799352

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@en

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@nl

type

label

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@en

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@nl

prefLabel

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@en

Cost effectiveness of pharmacogenomics: a critical and systematic review.

@nl

P1433

Q37799352-965CB2D2-53C0-4E6F-832B-9A58E8EBFC04

P1476

Q37799352-CDE6B4CA-41D1-43A4-B5B5-0D3CBA2CE60F

P2093

Q37799352-043D65D9-F0FE-47EB-8549-7080133B0148

Q37799352-8E3ED03A-1943-4C27-81F8-E9FB35BC985E

Q37799352-CF8ECE34-BE8C-4942-9557-C0EF70C22AF4

P2860

Q37799352-2C38B0D3-914E-4F1E-9DF0-C4E0FC943C29

Q37799352-596C28E6-F2C7-410C-86C6-77F032338543

Q37799352-59D05C62-3C9D-4947-9E4A-42EBCFEB3D45

Q37799352-C07D98BB-042C-46B3-B37D-9ED2CC293814

Q37799352-EC022B7B-B45E-4F87-B453-DD8698226AC3

Q37799352-FDDD7062-5DE7-4008-BCB9-6DB2AACF8FAB

P2888

Q37799352-6CC07557-AB32-44BF-B82F-5D3AE4A101A6

P304

Q37799352-268B80D1-8B87-43B7-A947-901B64AF0648

P31

Q37799352-4EAD61FC-BBE9-43BA-8750-D867E6AD5438

P356

Q37799352-098540CD-DFA9-4805-BBD3-385BF95FBAE5

P433

Q37799352-F5339720-FFFE-4CBC-A100-0B74315C559A

P478

Q37799352-6483E301-52A9-44EB-9A28-B29739ED1073

P50

Q37799352-05C2A9CE-D1B6-4C59-9F90-AD78206EE364

P577

Q37799352-ED92C3A6-C473-43BF-8D66-CE609C248397

P6179

Q37799352-EB1392D2-051F-4CC9-8921-8502A49662F1

P698

Q37799352-B33BCB2F-7885-4D72-95DF-9B6CFCDA1B80

P921

Q37799352-48EA9DA4-B807-4D6D-864E-FD96CD292A03

P356

11537410-000000000-00000

P1433

PharmacoEconomics

P1476

Cost effectiveness of pharmacogenomics: a critical and systematic review

@en

P2093

David L Veenstra

http://www.w3.org/2001/XMLSchema#string

Josh J Carlson

http://www.w3.org/2001/XMLSchema#string

Rahber Thariani

http://www.w3.org/2001/XMLSchema#string

P2860

Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis

P2888

11537410-000000000-00000

P304

1001-1013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11537410-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050916861

http://www.w3.org/2001/XMLSchema#string

P698

20936884

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics